Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

304 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Seroprevalence of SARS-CoV-2-Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy.
Cantini L, Bastianelli L, Lupi A, Pinterpe G, Pecci F, Belletti G, Stoico R, Vitarelli F, Moretti M, Onori N, Giampieri R, Rocchi MBL, Berardi R. Cantini L, et al. Among authors: lupi a. J Clin Med. 2021 Apr 4;10(7):1503. doi: 10.3390/jcm10071503. J Clin Med. 2021. PMID: 33916569 Free PMC article.
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab.
Lenci E, Cantini L, Pecci F, Cognigni V, Agostinelli V, Mentrasti G, Lupi A, Ranallo N, Paoloni F, Rinaldi S, Nicolardi L, Caglio A, Aerts S, Cortellini A, Ficorella C, Chiari R, Di Maio M, Dingemans AC, Aerts JGJV, Berardi R. Lenci E, et al. Among authors: lupi a. J Clin Med. 2021 Mar 2;10(5):1005. doi: 10.3390/jcm10051005. J Clin Med. 2021. PMID: 33801320 Free PMC article.
Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab.
Giampieri R, Lupi A, Ziranu P, Bittoni A, Pretta A, Pecci F, Persano M, Giglio E, Copparoni C, Crocetti S, Mandolesi A, Faa G, Coni P, Scartozzi M, Berardi R. Giampieri R, et al. Among authors: lupi a. Front Oncol. 2021 Sep 30;11:736104. doi: 10.3389/fonc.2021.736104. eCollection 2021. Front Oncol. 2021. PMID: 34660299 Free PMC article.
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients.
Mariani S, Puzzoni M, Giampieri R, Ziranu P, Pusceddu V, Donisi C, Persano M, Pinna G, Cimbro E, Parrino A, Spanu D, Pretta A, Lai E, Liscia N, Lupi A, Giglio E, Palomba G, Casula M, Pisano M, Palmieri G, Scartozzi M. Mariani S, et al. Among authors: lupi a. Front Oncol. 2022 Apr 21;12:852583. doi: 10.3389/fonc.2022.852583. eCollection 2022. Front Oncol. 2022. PMID: 35530345 Free PMC article.
Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis.
Lenci E, Marcantognini G, Cognigni V, Lupi A, Rinaldi S, Cantini L, Fiordoliva I, Carloni AL, Rocchi M, Zuccatosta L, Gasparini S, Berardi R. Lenci E, et al. Among authors: lupi a. Explor Target Antitumor Ther. 2021;2(3):227-239. doi: 10.37349/etat.2021.00043. Epub 2021 Jun 28. Explor Target Antitumor Ther. 2021. PMID: 36046436 Free PMC article.
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
Pretta A, Ziranu P, Giampieri R, Donisi C, Cimbro E, Spanu D, Lai E, Pecci F, Balconi F, Lupi A, Pozzari M, Persano M, Murgia S, Pusceddu V, Puzzoni M, Berardi R, Scartozzi M. Pretta A, et al. Among authors: lupi a. Dig Liver Dis. 2023 May;55(5):655-660. doi: 10.1016/j.dld.2022.11.012. Epub 2022 Dec 10. Dig Liver Dis. 2023. PMID: 36513569
304 results